Exclusive Ike Swetlitz Mylan offered EpiPen discounts to states in exchange for privileged status, documents show
Pharmalot Ed Silverman STAT Plus: Pharmalot, Pharmalittle: Merck and Scottish government conspired to trash environmental study
Pharmalot Ed Silverman STAT Plus: Some states consider making it easier to dispense EpiPen alternatives
Pharmalot Ed Silverman STAT Plus: FTC probes Mylan for possible antitrust violations involving EpiPen
Pharmalot Ed Silverman Hospitals are itching for a share of the Mylan settlement over Medicaid rebates
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Drug stocks hurt by fears that price hikes are abating
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Senator to hold hearing on Mylan’s Medicaid settlement
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month
The Pharmalot View Ed Silverman STAT Plus: Health officials should reject latest gambit by EpiPen maker to feed at the public trough
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Some docs say more patients want do-it-yourself EpiPens
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Chicago can proceed with lawsuit against opioid drug makers
Pharmalot Ed Silverman STAT Plus: Feds slam Mylan for misclassifying EpiPen, with ‘financial consequences’ to Medicaid
Pharmalot Ed Silverman Pharmalot, Pharmalittle: Novo Nordisk cutting 1,000 jobs amid diabetes drug price war